Buclizine

Cat. No.:	HY-A0128
CAS No.:	82-95-1
Molecular Formula:	$C_{28}H_{33}ClN_2$
Molecular Weight:	433.03
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Buclizine is an orally active antihistamine antiallergic compound. Buclizine is a potent teratogen in the rat and shows anti-tumor activity[1][2][3].

In Vitro

Buclizine (0.1-100 μM; 72 h) inhibits growth of MCF-7 cells[2].
Buclizine (9.625-77 μM; 72 h) arrests the cell cycle in the G1 phase in a dose-dependent manner[2].
Buclizine (0-75 μM; 72 h) decreases TCTP (translationally controlled tumor protein) and cell cycle regulatory proteins expression in MCF-7 cells, increases pro-apoptotic MCL-1S expression[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line:	MCF-7 cells
Concentration:	0-100 μM
Incubation Time:	72 hours
Result:	Showed considerable growth inhibition (IC_{50}=19.18 μM).

Cell Cycle Analysis[2]

Cell Line:	MCF-7 cells
Concentration:	9.625, 19.25, 38.5, and 77 μM
Incubation Time:	72 hours
Result:	Increased the percentages of cells in the G1 phase to 73% at 77 μM.

Western Blot Analysis[2]

Cell Line:	MCF-7 cells
Concentration:	0-75 μM
Incubation Time:	72 hours

Result:	Decreased TCTP expression by 40% at 75 μM. Decreased cyclin D1, cyclin D3, CDK2 and CDK4 expression after 72 h.

In Vivo

Buclizine dihydrochloride (30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation) shows potent teratogens in the rat[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighty-seven mature female rats weighing 240±20 grams[3]
Dosage:	30, 40, 60, 100, and 200 mg/kg
Administration:	30-200 mg/kg; tenth to fifteenth and twelfth to fifteenth days of gestation
Result:	Resulted in malformations in 100% of the young at a dose level of 60-100 mg/kg.

REFERENCES

[1]. Gamal A E Mostafa, et al. Buclizine. Profiles Drug Subst Excip Relat Methodol. 2011;36:1-33.

[2]. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget. 2016 Mar 29;7(13):16818-39.

[3]. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966 May 1;95(1):109-11.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA